Cardiovascular Consequences After COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04452630|
Recruitment Status : Recruiting
First Posted : June 30, 2020
Last Update Posted : June 30, 2020
The occurrence of cardiovascular complications in SARS-CoV-2 infections appears to be more frequent than in other viral respiratory infections, probably due to a singular pathophysiology of this coronavirus.
The lack of characterization of cardiovascular damages linked to Covid-19 could have medium and long-term consequences on the prognosis of patients. This problematic could lead to a second major public health problem linked to Covid-19 and it is therefore crucial to keep monitoring and screening patients at risk.
In this context of emerging infectious diseases, of poorly characterized cardiovascular damages during infection and of absence of data on the long-term evolution of the infection, the investigators propose to carry out a prospective and observational cohort study focused on the evaluation and the systematic cardiovascular follow up of patients who survived an episode of Covid-19, regardless of their cardiovascular profiles.
|Condition or disease||Intervention/treatment|
|Cardiovascular Consequences After an Episode of COVID 19||Other: Infectious Disease and Cardiology Clinical Consultations|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||The CardioPostCovid Study: Cardiovascular Consequences After COVID-19|
|Actual Study Start Date :||June 23, 2020|
|Estimated Primary Completion Date :||July 23, 2020|
|Estimated Study Completion Date :||November 30, 2021|
Covid 19 Patients
patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
Other: Infectious Disease and Cardiology Clinical Consultations
Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
- Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering [ Time Frame: 1 month ]Describe clinical, biological and imaging cardiovascular data 1 month after recovery from an episode of Covid-19
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04452630
|Contact: Franck THUNY, MDemail@example.com|
|Assistance Publique Hôpitaux de Marseille||Recruiting|
|Marseille, France, 13005|
|Contact: Franck THUNY, MD firstname.lastname@example.org|